Meet the Proteona Team in Nanjing, China
Innovative combined genomic and proteomic analysis platform for Immuno-Oncology and Single Cell BioMedical Applications
The Proteona team will be presenting two scientific talks in Nanjing in June 2019.
Dr Jonathan Scolnick and Dr Andreas Schmidt will meet with immunotherapy experts from the Nanjing Medical University on the 17th June, and discuss the application of Proteona’s ESCAPETM RNA sequencing platform in analysing cancer immunology and immunotherapy samples. On the 25th June, Dr Scolnick is invited to speak at the First Purple Mountain International Health Conference and Jiangbei New Area Precision Medicine Forum, where he will share about the importance of single-cell proteogenomic analysis for cell therapies.
Since the establishment of the Nanjing Biotech and Pharmaceutical Valley in 2011, Nanjing has attracted hundreds of local and international companies, forming a strong ecosystem for new drug development, clinical testing, and manufacturing. Do schedule a meeting with the Proteona team if you happen to be in the region.
For media queries, please contact:
Dr Andreas Schmidt
Proteona Pte. Ltd. is a biomedical company in Singapore, Germany, and the US that is pioneering the use of single cell proteogenomics to improve clinical outcomes in cancer. Using a combination of innovative single cell assays and AI-assisted bioinformatics, Proteona provides a comprehensive sample to answer service that enables users to phenotype cells using standard protein markers and gain a deeper understanding of cell activity based upon their gene expression profiles. Proteona is a spin-off from the National University of Singapore (NUS) and the Agency for Science, Technology and Research (A*STAR). Proteona is leading an international alliance to develop neutralizing antibodies against coronaviruses including SARS-CoV-2. In addition, Proteona supports partners developing COVID-19 therapies and vaccines by providing single cell immune profiling services.